{
  "url": "https://www.law.cornell.edu/regulations/new-york/9-NYCRR-113.3",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 9 § 113.3 - Practitioner Issuance of Certification",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 9 § 113.3 - Practitioner Issuance of Certification\n\nState Regulations\n(a) Requirements for Patient Certification. A\npractitioner who is eligible pursuant to 113.2 of this Part may issue a\ncertification for the use of medical cannabis by a qualifying patient subject\nto completion of subdivision (k) of this section. Such certification shall\ncontain: (1)\nthe practitioner's name, business\naddress, telephone number and email address; (2)\nthe practitioner's license number as\nissued by the New York State Department of Education; (3)\nthe practitioner's Drug Enforcement\n\nAdministration registration number for prescribing controlled substances in New\n\nYork State; (4)\na statement that\nthe practitioner is licensed and in good standing in New York State and\npossesses an active registration with the Drug Enforcement Administration for\nprescribing controlled substances in New York State; (5)\na statement that the practitioner is\ncaring for the patient in relation to the patient's condition; (6)\nthe patient's name, date of birth, residential address, telephone number and email address, if\navailable; (7)\nthe patient's\ncondition, which may include any of the condition(s) listed below: (i) cancer; (ii)\npositive status for human\nimmunodeficiency virus or acquired immune deficiency syndrome, provided that\nthe practitioner has obtained the patient's consent for disclosure of this\ninformation that meets the requirements set forth in section\n2782\nof the\n\nPublic Health Law; (iii)\namyotrophic lateral sclerosis; (iv)\n\nParkinson's disease; (v) multiple\nsclerosis; (vi)\ndamage to the\nnervous tissue of the spinal cord with objective neurological indication of\nintractable spasticity; (vii)\nepilepsy; (viii)\ninflammatory bowel\ndisease; (ix)\nneuropathies; (x) Huntington's\ndisease; (xi)\npost-traumatic stress\ndisorder; (xii)\npain that degrades\nhealth and functional capability where the use of medical cannabis is an\nalternative to opioid use; (xiii)\nsubstance use disorder; (xiv)\n\nAlzheimer's disease; (xv)\nmuscular\ndystrophy; (xvi)\ndystonia; (xvii)\nrheumatoid\narthritis; (xviii)\nautism; or\n(xix)\nany other condition\ncertified by the practitioner. (8)\na statement that by training or\nexperience, the practitioner is qualified to treat the condition, listed\npursuant to paragraph (7) of this subdivision; (9)\na statement that, in the practitioner's\nprofessional opinion and review of past treatments, the patient is likely to\nreceive therapeutic or palliative benefit from the primary or adjunctive\ntreatment with medical cannabis for the condition; (10)\nany recommendations or limitations the\npractitioner makes to the certified patient or the patient's designated\ncaregiver; (11)\nto the extent that\na practitioner seeks to authorize the use of medical cannabis by a patient who\ntemporarily resides in New York State for the purpose of receiving care and\ntreatment from the practitioner, the practitioner shall so state on the\npatient's certification; and\n(12)\nthe practitioner's signature and date upon the certification and a signed\ncertification provided to the patient. (b) Additional Requirements for Patient\n\nCertification where the patient is under the age of eighteen (18) or is\notherwise incapable of consent. A practitioner who is eligible pursuant to\nsection\n113.2\nof this Part may issue a\ncertification for the use of medical cannabis by a qualifying patient, where\nsuch a patient is under the age of eighteen (18) or is otherwise incapable of\nconsent, subject to completion of subdivision (a) and (k) of this section and\nsuch additional information on the certification as follows: (1)\nan attestation that the practitioner\nobtained a statement from the person responsible for making health care\ndecisions that they are: (i) legally\nauthorized to make health care decisions on behalf of the patient under the age\nof eighteen (18) or otherwise incapable of consent; (ii)\nconsenting on the patient's behalf, the\nuse of medical cannabis product(s) and any device used for its administration; and\n(iii)\nidentifying the\ndesignated caregiver for the patient under the age of eighteen (18) or\notherwise incapable of consent, including such designated caregiver's full\nname, address, date of birth, telephone number and email address, if available; and\n(2)\nthe designated\ncaregiver identified in subparagraph (iii) of paragraph (1) of this section\nshall be exempt from the requirements set forth in section\n113.5\nof this Part. (c) The practitioner shall provide\nthe signed certification to the certified patient, or for those individuals\nunder the age of eighteen (18) or incapable of consent, the person responsible\nfor making healthcare decisions pursuant to paragraph (1) of subdivision (b) of\nthis section. (d) The designated\ncaregiver who is identified in accordance with section\n113.3\n(b) of this\n\nPart, shall be deemed registered with the Office. (e) Should the person responsible for making\nhealth care decisions identified in accordance with section\n113.3\n(b) of this\n\nPart or the parent or legal guardian in accordance with Cannabis Law Section\n32(3)(b)(ii) decide to change or elect to add additional designated\ncaregiver(s), such designated caregiver must comply with the registration\nrequirements of section\n113.5\nof this Part. (f) Should the person responsible for making\nhealth care decisions identified in accordance with section\n113.3\n(b) of this\n\nPart or the parent or legal guardian in accordance with Cannabis Law Section\n32(3)(b)(ii) decide to change the designated caregiver identified in section\n113.3\n(b)(1)(iii)\nof this Part, they shall notify the practitioner to update the requirements set\nforth in section\n113.3\nof this Part. (g) Requirements of Patient Special\n\nCertification. The practitioner may issue a special certification if the\npatient's condition is progressive and degenerative or that delay in the\npatient's certified medical use of cannabis poses a risk to the patient's life\nor health. Such certification shall be on a form provided by the Office and\nshall contain the requirements set forth in subdivision (a) of this\nsection. (h) Expiration of\n\nCertification. (1)\n\nThe certification shall\nstate the date upon which the certification shall expire, which shall be no\nlonger than one (1) year after the date it was issued, unless the patient is\nterminally ill. (2)\n\nIf the\npractitioner issues a certification to a patient who is terminally ill, the\ncertification shall not expire until the patient's death or the practitioner\nre-issues the certification to terminate the certification on an earlier\ndate. (3)\n\nIf the practitioner\nissues a certification to a patient who is not a resident of New York State but\nis receiving care and treatment in this state, the certification shall be valid\nfor a period of time which is no longer than the patient is reasonably\nanticipated to be residing in New York State for the purposes of care and\ntreatment, but in no event shall it be valid for more than one (1) year after\nthe date it was issued. (i) Submission of Certification to the\n\nOffice. Practitioners shall utilize a form, which may be in an electronic\nformat, developed by the Office for the certification required in subdivision\n(a) of this section. The practitioner shall submit to the Office, the\ninformation required by subdivision (a) of this section, in a manner determined\nby the Office, including by electronic transmission through a secure\nwebsite. (j) Record Retention. The\npractitioner shall also maintain a copy of the signed certification, which\nshall include all information required in subdivision (a) of this section, and\nfor those under the age of eighteen (18) or incapable of consent, all the\nadditional information required in subdivision (b) of this section, for a\nperiod of five (5) years, in the patient's medical record. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 9\n§\n113.3\n\nAdopted\n\nNew\n\nYork State Register February 22, 2023/Volume XLV, Issue 08, eff. 2/22/2023\n\nAmended\n\nNew\n\nYork State Register March 27, 2024/Volume XLVI, Issue 13, eff. 3/27/2024\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. (a) Requirements for Patient Certification. A\npractitioner\nwho is eligible pursuant to 113.2 of this Part\nmay\nissue a certification for the use of medical cannabis by a qualifying patient subject to completion of subdivision (k) of this section. Such certification shall contain: (1)\nthe\npractitioner\n's name, business address, telephone number and email address; (2)\nthe\npractitioner\n's\nlicense\nnumber as issued by the New York\n\nState\n\nDepartment\nof Education; (3)\nthe\npractitioner\n's Drug Enforcement Administration registration number for prescribing controlled substances in New York\n\nState; (4)\na statement that the\npractitioner\nis licensed and in good standing in New York\n\nState\nand possesses an active registration with the Drug Enforcement Administration for prescribing controlled substances in New York\n\nState; (5)\na statement that the\npractitioner\nis\ncaring for\nthe patient in relation to the patient's\ncondition; (6)\nthe patient's name, date of birth, residential address, telephone number and email address, if available; (7)\nthe patient's\ncondition, which\nmay\ninclude any of the\ncondition\n(s) listed below: (i) cancer; (ii)\npositive status for human immunodeficiency virus or acquired immune deficiency syndrome, provided that the\npractitioner\nhas obtained the patient's consent for disclosure of this information that meets the requirements set forth in section\n2782\nof the Public Health\n\nLaw; (iii)\namyotrophic lateral sclerosis; (iv)\n\nParkinson's disease; (v) multiple sclerosis; (vi)\ndamage to the nervous tissue of the spinal cord with objective neurological indication of intractable spasticity; (vii)\nepilepsy; (viii)\ninflammatory bowel disease; (ix)\nneuropathies; (x) Huntington's disease; (xi)\npost-traumatic stress disorder; (xii)\npain that degrades health and functional capability where the use of medical cannabis is an alternative to opioid use; (xiii)\nsubstance use disorder; (xiv)\n\nAlzheimer's disease; (xv)\nmuscular dystrophy; (xvi)\ndystonia; (xvii)\nrheumatoid arthritis; (xviii)\nautism; or\n(xix)\nany other\ncondition\ncertified by the\npractitioner. (8)\na statement that by training or experience, the\npractitioner\nis qualified to treat the\ncondition, listed pursuant to paragraph (7)\nof this subdivision; (9)\na statement that, in the\npractitioner\n's professional opinion and review of past treatments, the patient is likely to receive therapeutic or palliative benefit from the primary or adjunctive treatment with medical cannabis for the\ncondition; (10)\nany recommendations or limitations the\npractitioner\nmakes to the\ncertified patient\nor the patient's designated caregiver; (11)\nto the extent that a\npractitioner\nseeks to authorize the use of medical cannabis by a patient who temporarily resides in New York\n\nState\nfor the purpose of receiving care and treatment from the\npractitioner, the\npractitioner\nshall so\nstate\non the patient's certification; and\n(12)\nthe\npractitioner\n's signature and date upon the certification and a signed certification provided to the patient. (b) Additional Requirements for Patient Certification where the patient is under the age of eighteen (18) or is otherwise incapable of consent. A\npractitioner\nwho is eligible pursuant to section\n113.2\nof this Part\nmay\nissue a certification for the use of medical cannabis by a qualifying patient, where such a patient is under the age of eighteen (18) or is otherwise incapable of consent, subject to completion of subdivision (a) and (k) of this section and such additional information on the certification as follows: (1)\nan attestation that the\npractitioner\nobtained a statement from the\nperson\nresponsible for making health care decisions that they are: (i) legally authorized to make health care decisions on behalf of the patient under the age of eighteen (18) or otherwise incapable of consent; (ii)\nconsenting on the patient's behalf, the use of\nmedical cannabis product\n(s) and any device used for its administration; and\n(iii)\nidentifying the designated caregiver for the patient under the age of eighteen (18) or otherwise incapable of consent, including such designated caregiver's full name, address, date of birth, telephone number and email address, if available; and\n(2)\nthe designated caregiver identified in subparagraph (iii) of paragraph (1) of this section shall be exempt from the requirements set forth in section\n113.5\nof this Part. (c) The\npractitioner\nshall provide the signed certification to the\ncertified patient, or for those individuals under the age of eighteen (18) or incapable of consent, the\nperson\nresponsible for making healthcare decisions pursuant to paragraph (1) of subdivision (b) of this section. (d) The designated caregiver who is identified in accordance with section\n113.3\n(b) of this Part, shall be deemed registered with the\n\nOffice. (e) Should the\nperson\nresponsible for making health care decisions identified in accordance with section\n113.3\n(b) of this Part or the parent or legal guardian in accordance with Cannabis\n\nLaw\n\nSection 32(3)(b)(ii) decide to change or elect to add additional designated caregiver(s), such designated caregiver must comply with the registration requirements of section\n113.5\nof this Part. (f) Should the\nperson\nresponsible for making health care decisions identified in accordance with section\n113.3\n(b) of this Part or the parent or legal guardian in accordance with Cannabis\n\nLaw\n\nSection 32(3)(b)(ii) decide to change the designated caregiver identified in section\n113.3\n(b)(1)(iii)\nof this Part, they shall notify the\npractitioner\nto update the requirements set forth in section\n113.3\nof this Part. (g) Requirements of Patient Special Certification. The\npractitioner\nmay\nissue a special certification if the patient's\ncondition\nis progressive and degenerative or that delay in the patient's\ncertified medical\nuse of cannabis poses a risk to the patient's life or health. Such certification shall be on a\nform\nprovided by the\n\nOffice\nand shall contain the requirements set forth in subdivision (a) of this section. (h) Expiration of Certification. (1)\n\nThe certification shall\nstate\nthe date upon which the certification shall expire, which shall be no longer than one (1) year after the date it was issued, unless the patient is terminally ill. (2)\n\nIf the\npractitioner\nissues a certification to a patient who is terminally ill, the certification shall not expire until the patient's death or the\npractitioner\nre-issues the certification to terminate the certification on an earlier date. (3)\n\nIf the\npractitioner\nissues a certification to a patient who is not a resident of New York\n\nState\nbut is receiving care and treatment in this\nstate, the certification shall be valid for a period of time which is no longer than the patient is reasonably anticipated to be residing in New York\n\nState\nfor the purposes of care and treatment, but in no event shall it be valid for more than one (1) year after the date it was issued. (i) Submission of Certification to the\n\nOffice. Practitioners shall utilize a\nform, which\nmay\nbe in an electronic format, developed by the\n\nOffice\nfor the certification required in subdivision (a) of this section. The\npractitioner\nshall submit to the\n\nOffice, the information required by subdivision (a) of this section, in a manner determined by the\n\nOffice, including by electronic transmission through a secure website. (j) Record\n\nRetention. The\npractitioner\nshall also maintain a copy of the signed certification, which shall include all information required in subdivision (a) of this section, and for those under the age of eighteen (18) or incapable of consent, all the additional information required in subdivision (b) of this section, for a period of five (5) years, in the patient's medical\nrecord. (k) Consultation of Prescription Monitoring\n\nProgram\n\nRegistry. Prior to issuing, modifying or renewing a certification, the\npractitioner\nshall consult the prescription monitoring\nprogram\nregistry pursuant to section\n3343-a\nof the Public Health\n\nLaw\nfor the purpose of reviewing a patient's controlled substance history. Practitioners\nmay\nauthorize a designee to consult the prescription monitoring\nprogram\nregistry on their behalf, provided that such\ndesignation\nis in accordance with section\n3343-a\nof the Public Health\n\nLaw. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 9\n§\n113.3\n\nAdopted\n\nNew York\n\nState\n\nRegister February 22, 2023/Volume XLV, Issue 08, eff. 2/22/2023",
  "url_type": "regulation",
  "source_index": 51514
}